All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.

2024-06-21T09:41:20.000Z

BVd vs DVd in patients with R/R MM: Results from the DREAMM-7 trial

Jun 21, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.

Bookmark this article


Belantamab mafodotin, a BCMA-targeted antibody-drug conjugate, has demonstrated efficacy in patients with multiple myeloma (MM). The phase III DREAMM-7 trial (NCT04246047) is assessing the safety and efficacy of belantamab mafodotin in combination with bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in patients with relapsed/refractory (R/R) MM with ≥1 prior line of therapy.1 Results from this trial were presented by Mateos1 during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. 


Key learnings:

The DREAMM-7 study met its primary endpoint of progression-free survival (PFS): median PFS was 36.6 months vs 13.4 months in the BVd and DVd arms, respectively (p < 0.00001); this benefit was sustained across prespecified subgroups, including patients with lenalidomide-refractory or high-risk cytogenetic MM.

BVd also improved overall survival (OS) vs DVd, with 12-month and 18-month OS rates of 87% vs 81% and 84% vs 73%, respectively. 

BVd was associated with a higher ≥complete response (CR) rate (34.6% vs 17.1%) and a higher ≥CR with measurable residual disease-negativity rate (24.7% vs 9.6%) when compared with DVd. 

The safety profile of BVd was consistent with that of the individual agents, and ocular adverse events were generally manageable, leading to discontinuation in 9% of patients.

These results suggest that BVd could be a new standard of care for patients with R/R MM.


  1. Mateos MV. Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM). Abstract #439572. American Society of Clinical Oncology Annual Meeting; May 30 – Jun 3, 2024; Chicago, US.

Your opinion matters

Which dosing schedule for belantamab mafodotin do you think is optimal for providing an efficacy benefit while managing toxicities?
2 votes - 42 days left ...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox